Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2

@article{Stenehjem2016ExtensionOO,
  title={Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2},
  author={David D Stenehjem and Michael Toole and Joseph Alan Merriman and Kinjal J. Parikh and Stephanie D. Daignault and Sarah Scarlett and Peg Esper and Katherine Skinner and Aaron M Udager and Srinivas Kiran Tantravahi and David P Gill and Alli M. Straubhar and Archana M. Agarwal and Kenneth F. Grossmann and Wolfram E Samlowski and Bruce R Redman and Neeraj Agarwal and Ajjai Alva},
  journal={Cancer Immunology, Immunotherapy},
  year={2016},
  volume={65},
  pages={941-949}
}
In metastatic renal cell carcinoma (mRCC), survival benefit associated with objective response rates of 16–20 % with high-dose interleukin-2 (HDIL-2) is well established and discussed. Based on recently emerged data on efficacy of cancer immunotherapy, we hypothesized that the survival benefit with HDIL-2 extends beyond those achieving objective responses, i.e., to those who achieve stable disease as the best response to treatment. All sequential treatment naïve mRCC patients treated with HDIL… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
5 Citations
31 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 31 references

optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

  • GR Hudes, MA Carducci, report Choueiri TK et al NCCN Task force
  • J Natl Compr Cancer Netw 9(Suppl 1):S1–S29 949…
  • 2016
1 Excerpt

Similar Papers

Loading similar papers…